Compare Stocks → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALLRNASDAQ:BLPHNASDAQ:MTPNASDAQ:VBLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.00-18.7%$4.90$0.95▼$372.00$2.39M0.546.40 million shs7.56 million shsBLPHBellerophon Therapeutics$0.06$0.06$0.03▼$11.15$764K0.6921,978 shsN/AMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-18.70%-31.51%-78.59%-88.95%-99.67%BLPHBellerophon Therapeutics0.00%+12.82%+15.31%+9.65%-99.28%MTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+2,835.48%Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.0505 of 5 stars0.02.00.00.03.00.00.0BLPHBellerophon Therapeutics1.2463 of 5 stars3.00.00.04.80.60.00.6MTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity TherapeuticsN/AN/AN/AN/ABLPHBellerophon Therapeutics2.00Hold$2.003,100.00% UpsideMTPBiodexa PharmaceuticalsN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A($18.62) per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00VBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.90MN/A0.00N/AN/AN/AN/A-91.78%5/9/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)MTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/AVBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A0.140.14BLPHBellerophon TherapeuticsN/A3.963.96MTPBiodexa PharmaceuticalsN/AN/AN/AVBLTVascular BiogenicsN/A4.634.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%BLPHBellerophon Therapeutics10.61%MTPBiodexa Pharmaceuticals4.21%VBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%BLPHBellerophon Therapeutics5.20%MTPBiodexa Pharmaceuticals0.34%VBLTVascular Biogenics6.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics52.39 million2.38 millionNot OptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableVBLT, ALLR, BLPH, and MTP HeadlinesSourceHeadlineTommy Garten elected to VBL Hall of Fametherecorderonline.com - March 28 at 1:31 PMControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemnature.com - February 21 at 3:29 PMVascular News and Researchnews-medical.net - November 25 at 2:28 PMVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26msn.com - November 3 at 12:39 AMNotable Labs Closes Merger Transaction With VBL Therapeuticsfinance.yahoo.com - October 16 at 3:55 PMVBL Therapeutics Announces Results of Annual and Special Shareholder Meetingfinance.yahoo.com - October 12 at 3:13 PMVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meetingfinance.yahoo.com - October 4 at 8:40 AMVascular Biogenics Rises on Presentation Hypefinance.yahoo.com - September 9 at 12:00 PMVBLT Stock Sees Decline of Approximately -0.22% in Last Five Daysknoxdaily.com - September 7 at 9:15 PMVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECfinance.yahoo.com - September 6 at 7:30 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 7:00 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 3:04 PMVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 8:09 AMMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsknoxdaily.com - July 26 at 4:10 PMVascular Biogenics (NASDAQ: VBLT)fool.com - July 23 at 5:52 PMRecent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)knoxdaily.com - July 12 at 4:20 PMVBLT Stock Sees Decline of Approximately -4.31% in Last Five Daysknoxdaily.com - July 7 at 2:11 PMDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interestknoxdaily.com - June 23 at 8:26 PMThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgerymedscape.com - May 18 at 1:35 AMVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:03 PMDeveloping a Patient-Centered Approach to Vascular Access Device Selectionmedscape.com - May 10 at 8:52 AMCADASIL: The Most Common Hereditary Subcortical Vascular Dementiamedscape.com - May 5 at 1:05 AMAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Diseasemedscape.com - May 2 at 8:00 PMVascular Biogenics Stock (NASDAQ:VBLT), Dividendsbenzinga.com - April 4 at 1:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAllarity TherapeuticsNASDAQ:ALLRAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Biodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.